CN102399261B - 具有血管紧张素转化酶c-端选择性抑制活性的三肽及其应用和组合物 - Google Patents
具有血管紧张素转化酶c-端选择性抑制活性的三肽及其应用和组合物 Download PDFInfo
- Publication number
- CN102399261B CN102399261B CN201010274501.0A CN201010274501A CN102399261B CN 102399261 B CN102399261 B CN 102399261B CN 201010274501 A CN201010274501 A CN 201010274501A CN 102399261 B CN102399261 B CN 102399261B
- Authority
- CN
- China
- Prior art keywords
- tripeptides
- tripeptide
- converting enzyme
- ace
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000000694 effects Effects 0.000 title claims abstract description 21
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 title claims abstract description 19
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 title claims abstract description 16
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 title claims abstract 6
- 239000000203 mixture Substances 0.000 title abstract description 17
- 230000005764 inhibitory process Effects 0.000 title abstract description 10
- 210000004899 c-terminal region Anatomy 0.000 title abstract 2
- 239000003814 drug Substances 0.000 claims abstract description 15
- 235000013376 functional food Nutrition 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims description 5
- 108010072661 Angiotensin Amide Proteins 0.000 claims description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 2
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 25
- 150000001413 amino acids Chemical group 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 238000010532 solid phase synthesis reaction Methods 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 102000008192 Lactoglobulins Human genes 0.000 description 2
- 108010060630 Lactoglobulins Proteins 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229960004799 tryptophan Drugs 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- XRDUNZCLSCKAMY-BXRBKJIMSA-N (2s)-2,4-bis(azanyl)-4-oxidanylidene-butanoic acid Chemical compound OC(=O)[C@@H](N)CC(N)=O.OC(=O)[C@@H](N)CC(N)=O XRDUNZCLSCKAMY-BXRBKJIMSA-N 0.000 description 1
- AAXWBCKQYLBQKY-IRXDYDNUSA-N (2s)-2-[[(2s)-2-[(2-benzamidoacetyl)amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)C=1C=CC=CC=1)C1=CN=CN1 AAXWBCKQYLBQKY-IRXDYDNUSA-N 0.000 description 1
- HOZBSSWDEKVXNO-BXRBKJIMSA-N (2s)-2-azanylbutanedioic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CC(O)=O HOZBSSWDEKVXNO-BXRBKJIMSA-N 0.000 description 1
- XDDMZVMWZMSAMX-JHNJPSDUSA-N (2s,3s)-2-azanyl-3-methyl-pentanoic acid Chemical compound CC[C@H](C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O XDDMZVMWZMSAMX-JHNJPSDUSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101710170564 Bradykinin-potentiating peptide Proteins 0.000 description 1
- 101000984728 Chiropsoides quadrigatus Angiotensin-converting enzyme inhibitory peptide Proteins 0.000 description 1
- 229930182832 D-phenylalanine Natural products 0.000 description 1
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- -1 IKQ Chemical compound 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- OHGVVSJWNCLVAR-FPAZSGHZSA-N N[C@@H](C(C)C)C(=O)O.C(CC)N[C@@H](CCO)C(=O)O Chemical compound N[C@@H](C(C)C)C(=O)O.C(CC)N[C@@H](CCO)C(=O)O OHGVVSJWNCLVAR-FPAZSGHZSA-N 0.000 description 1
- 108010007500 RXP 407 Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 108010016268 hippuryl-histidyl-leucine Proteins 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 235000021581 juice product Nutrition 0.000 description 1
- UJKDYMOBUGTJLZ-RUCXOUQFSA-N ksc605q1h Chemical compound OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CCC(O)=O UJKDYMOBUGTJLZ-RUCXOUQFSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
名称 | 单字母符号 | 名称 | 单字母符号 |
丙氨酸(alanine) | A | 亮氨酸(leucine) | L |
精氨酸(arginine) | R | 赖氨酸(lysine) | K |
天冬酰胺(asparagine) | N | 甲硫氨酸(methionine) | M |
天冬氨酸(aspartic acid) | D | 苯丙氨酸(phenylalanine) | F |
半胱氨酸(cysteine) | C | 脯氨酸(proline) | P |
谷氨酰胺(glutanine) | Q | 丝胺酸(serine) | S |
谷氨酸(glutamic acid) | E | 苏氨酸(threonine) | T |
甘氨酸(Glicine) | G | 色氨酸(tryptophan) | W |
组氨酸(histidine) | H | 酪氨酸(tyrosine) | Y |
异亮氨酸(isoleucine) | I | 颉氨酸(valine) | V |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010274501.0A CN102399261B (zh) | 2010-09-07 | 2010-09-07 | 具有血管紧张素转化酶c-端选择性抑制活性的三肽及其应用和组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010274501.0A CN102399261B (zh) | 2010-09-07 | 2010-09-07 | 具有血管紧张素转化酶c-端选择性抑制活性的三肽及其应用和组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102399261A CN102399261A (zh) | 2012-04-04 |
CN102399261B true CN102399261B (zh) | 2014-06-25 |
Family
ID=45881962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010274501.0A Active CN102399261B (zh) | 2010-09-07 | 2010-09-07 | 具有血管紧张素转化酶c-端选择性抑制活性的三肽及其应用和组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102399261B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103275177B (zh) * | 2013-06-24 | 2015-08-12 | 南京财经大学 | 具有肾素和ace双重抑制活性的小肽、其制备方法及应用 |
WO2017013172A1 (en) * | 2015-07-23 | 2017-01-26 | Stichting Katholieke Universiteit | Novel inhibitors of p-glycoprotein |
CN107312064A (zh) * | 2017-07-26 | 2017-11-03 | 盐城卫生职业技术学院 | 一种抗高血压活性肽GABA‑The‑Pro及应用和药物组合物 |
CN108003229B (zh) * | 2017-11-13 | 2021-04-20 | 江苏大学 | 玉米醇溶蛋白ace抑制肽及作为保健食品应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002080495A (ja) * | 2000-09-04 | 2002-03-19 | Univ Kyoto | 新規な血清コレステロール低下ペプチド |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4727770B2 (ja) * | 1997-09-26 | 2011-07-20 | カルピス株式会社 | 尿中カテコールアミン低下、尿中ノルアドレナリン低下、尿中ドーパミン低下及びFischer比低下の少なくとも1つの軽減剤 |
TWI344371B (en) * | 2003-03-18 | 2011-07-01 | Suntory Holdings Ltd | Angiotensin-converting enzyme inhibitory peptides |
UA87278C2 (ru) * | 2003-08-01 | 2009-07-10 | Калпис Ко., Лтд. | Пептиды, которые биологически не разлагаются; ингибитор ангиотензинпревращающего фермента, лекарственное средство и функциональный пищевой продукт |
CN101429231B (zh) * | 2007-11-06 | 2011-11-30 | 光明乳业股份有限公司 | 一种抗高血压活性三肽及其制备方法和应用 |
-
2010
- 2010-09-07 CN CN201010274501.0A patent/CN102399261B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002080495A (ja) * | 2000-09-04 | 2002-03-19 | Univ Kyoto | 新規な血清コレステロール低下ペプチド |
Non-Patent Citations (2)
Title |
---|
Annegret Biegel等.Structural Requirements for the Substrates of the H+/Peptide Cotransporter PEPT2 Determined by Three-Dimensional Quantitative Structure-Activity Relationship Analysis.《J. Med. Chem.》.2006,4286-4296. |
Structural Requirements for the Substrates of the H+/Peptide Cotransporter PEPT2 Determined by Three-Dimensional Quantitative Structure-Activity Relationship Analysis;Annegret Biegel等;《J. Med. Chem.》;20061231;4286-4296 * |
Also Published As
Publication number | Publication date |
---|---|
CN102399261A (zh) | 2012-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Liu et al. | Exploration of the molecular interactions between angiotensin-I-converting enzyme (ACE) and the inhibitory peptides derived from hazelnut (Corylus heterophylla Fisch.) | |
Chen et al. | Purification and characterization of a novel angiotensin-I converting enzyme (ACE) inhibitory peptide derived from enzymatic hydrolysate of grass carp protein | |
Jung et al. | Angiotensin I-converting enzyme inhibitory peptide from yellowfin sole (Limanda aspera) frame protein and its antihypertensive effect in spontaneously hypertensive rats | |
Sonklin et al. | Identification of antihypertensive peptides from mung bean protein hydrolysate and their effects in spontaneously hypertensive rats | |
Gu et al. | LC–MS/MS coupled with QSAR modeling in characterising of angiotensin I-converting enzyme inhibitory peptides from soybean proteins | |
Wang et al. | Purification and identification of a ACE inhibitory peptide from oyster proteins hydrolysate and the antihypertensive effect of hydrolysate in spontaneously hypertensive rats | |
Pan et al. | Purification and characterisation of a novel angiotensin-I converting enzyme (ACE)-inhibitory peptide derived from the enzymatic hydrolysate of Enteromorpha clathrata protein | |
Lin et al. | Pilot-scale production of low molecular weight peptides from corn wet milling byproducts and the antihypertensive effects in vivo and in vitro | |
Forghani et al. | Purification and characterization of angiotensin converting enzyme-inhibitory peptides derived from Stichopus horrens: Stability study against the ACE and inhibition kinetics | |
Fahmi et al. | Production of angiotensin I converting enzyme inhibitory peptides from sea bream scales | |
Bhaskar et al. | Purification, identification, and characterization of novel angiotensin I-converting enzyme (ACE) inhibitory peptides from alcalase digested horse gram flour | |
Gu et al. | Angiotensin I-converting enzyme inhibitory activity of low-molecular-weight peptides from Atlantic salmon (Salmo salar L.) skin | |
Lee et al. | Antihypertensive effect of novel angiotensin I converting enzyme inhibitory peptide from chum salmon (Oncorhynchus keta) skin in spontaneously hypertensive rats | |
CN102399262B (zh) | 具有血管紧张素转化酶抑制活性的三肽及其应用和组合物 | |
Wu et al. | Purification and identification of Angiotensin-I Converting Enzyme (ACE) inhibitory peptide from lizard fish (Saurida elongata) hydrolysate | |
Zhao et al. | A novel ACE inhibitory peptide isolated from Acaudina molpadioidea hydrolysate | |
Suetsuna et al. | Identification of an antihypertensive peptide from peptic digest of wakame (Undaria pinnatifida) | |
Asoodeh et al. | Purification and characterisation of angiotensin I converting enzyme inhibitory peptides from lysozyme hydrolysates | |
Lee et al. | Tyr-Pro-Lys, an angiotensin I-converting enzyme inhibitory peptide derived from broccoli (Brassica oleracea Italica) | |
Pokora et al. | An attractive way of egg white protein by-product use for producing of novel anti-hypertensive peptides | |
US9006171B2 (en) | Angiotensin converting enzyme inhibitory peptide | |
Zarei et al. | In vitro and in vivo antihypertensive activity of palm kernel cake protein hydrolysates: Sequencing and characterization of potent bioactive peptides | |
CN102399261B (zh) | 具有血管紧张素转化酶c-端选择性抑制活性的三肽及其应用和组合物 | |
Gildberg et al. | Angiotensin I-converting enzyme inhibitory activity in a hydrolysate of proteins from Northern shrimp (Pandalus borealis) and identification of two novel inhibitory tri-peptides | |
Lee et al. | Purification and characterization of a novel angiotensin I-converting enzyme inhibitory peptide derived from an enzymatic hydrolysate of duck skin byproducts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: CHINA AGRICULTURAL UNIVERSITY Free format text: FORMER OWNER: REN FAZHENG Effective date: 20150312 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Ren Fazheng Inventor after: Jiang Lu Inventor after: Zhang Shunliang Inventor after: Guo Huiyuan Inventor before: Jiang Lu Inventor before: Ren Fazheng Inventor before: Zhang Shunliang Inventor before: Guo Huiyuan |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: JIANG LU REN FAZHENG ZHANG SHUNLIANG GUO HUIYUAN TO: REN FAZHENG JIANG LU ZHANG SHUNLIANG GUO HUIYUAN Free format text: CORRECT: ADDRESS; FROM: 100093 HAIDIAN, BEIJING TO: 100083 HAIDIAN, BEIJING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150312 Address after: 100083 Haidian District Qinghua East Road, No. 17, Beijing Patentee after: CHINA AGRICULTURAL University Address before: 100093 Beijing Haidian District City Garden 12 Building No. 1506, producing up new Patentee before: Ren Fazheng |
|
TR01 | Transfer of patent right |
Effective date of registration: 20231206 Address after: 462000 Intersection of Wenming Road and China National Highway 107, Yancheng District, Luohe City, Henan Province Patentee after: Zhongyuan Food Laboratory Address before: 100083 No. 17 Qinghua East Road, Beijing, Haidian District Patentee before: CHINA AGRICULTURAL University |
|
TR01 | Transfer of patent right |